Clinical trials
Chemotherapy clinical trials
Below are recruiting chemotherapy clinical trials, each written for real people, not researchers. We’re tracking 2,011 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07296705RecruitingPhase 2
New drug combo to save the bladder in HER2-positive bladder cancer
This trial tests combining two newer drugs (zanidatamab and tislelizumab) with standard chemotherapy before bladder surgery. The goal is to shrink the tumor so the bladder can be saved instead of removed.
Fuzhou, FujianAges 18–85 - NCT05268692RecruitingPhase 2/Phase 3
Pancreatic cancer chemo before surgery, then two drug combinations
This trial studies giving chemotherapy before planned surgery for pancreatic cancer, followed by additional treatment with two drug combinations. It may help shrink the cancer and improve how well surgery works.
KochiAges 18–85 - NCT06196697RecruitingPhase 2
New immunotherapy combo for advanced stomach cancer
This clinical trial is testing a combination of two immunotherapy drugs (AK104 and AK112) plus chemotherapy as the first treatment for advanced stomach or gastroesophageal junction cancer. It aims to see if this combination helps control the cancer better than standard therapy.
HarbinAges 18–75 - NCT03961373RecruitingPhase 3
Standard vs longer lymph node surgery after chemo for stomach cancer
This study compares two surgical approaches to remove lymph nodes after you’ve already had chemotherapy for stomach cancer. It aims to see whether removing lymph nodes in a more extended way improves outcomes without causing unacceptable side effects.
SienaAges 18–80 - NCT05651802Recruiting
Brain MRI follow-up with or without preventive scans in SCLC
This study tests whether adding a preventive brain procedure (PCI) to standard follow-up brain MRIs helps people with limited-stage small-cell lung cancer stay disease-free longer. It compares “MRI only” versus “MRI plus PCI” after the cancer has fully responded to initial treatment.
Guangzhou, GuangdongAges 18 years+ - NCT06727981Recruiting
Immunotherapy as first treatment for stomach cancer
This trial tests immunotherapy as the first treatment for people with advanced or locally advanced stomach cancer. It may help if you haven't had any prior anti-cancer therapy and are starting treatment soon.
Jinan, ShandongAges 18–100 - NCT05214222RecruitingPhase 2
New treatment for advanced esophageal cancer after past therapy
This Phase 2 trial tests penpulimab plus chemotherapy (with or without an added targeted pill called anlotinib) in people with advanced esophageal squamous cell carcinoma. It aims to slow tumor growth and improve outcomes, especially for patients who can’t have curative surgery or radiation.
Guangzhou, GuangdongAges 18–75 - NCT06711068Recruiting
Chemotherapy plus targeted therapy for HER2+ early breast cancer
This trial tests whether adding targeted therapy to chemotherapy after surgery can help prevent HER2-positive early breast cancer from coming back. It is for patients whose cancer has not spread to lymph nodes and who have certain tumor sizes and features.
Beijing, Beijing MunicipalityAges Any age - NCT06700369Recruiting
Lowering chemo with targeted therapy for HER2+ breast cancer
This study looks at whether using targeted therapy can reduce the amount of chemotherapy needed before surgery for HER2-positive breast cancer. It aims to find a safer, equally effective treatment plan.
Beijing, Beijing MunicipalityAges Any age - NCT05934448RecruitingPhase 2
CAR T plus pembrolizumab for relapsed lymphoma after prior treatment
This Phase 2 trial studies CAR T-cell therapy combined with pembrolizumab for certain hard-to-treat lymphomas that have come back or did not respond. It aims to improve tumor response and outcomes after you’ve already tried standard treatments.
Boston, MassachusettsAges 18 years+ - NCT06610799RecruitingPhase 1
Study of IBI363 for first-line advanced gastric cancer
This trial tests a new drug called IBI363 in patients with advanced gastric or gastroesophageal junction cancer who have not yet received any treatment. The goal is to see if the drug can help shrink tumors or slow the cancer's growth.
Hangzhou, ZhejiangAges 18–75 - NCT07384234RecruitingPhase 2
Testing a new drug plus chemo for stomach cancer with belly spread
This trial tests a new immunotherapy drug (SHR-1701) combined with chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen (peritoneal metastasis) but not to other organs like the liver or lungs. The goal is to see if this combination can help shrink or control the cancer before any surgery.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06595108Recruiting
Targeted therapy and radiation for advanced liver cancer
This trial tests a combination of immunotherapy (atezolizumab), targeted therapy (bevacizumab), and targeted radiation for advanced liver cancer that cannot be surgically removed. The goal is to see if this approach helps control the cancer.
Yongin-siAges 19–80 - NCT06569485RecruitingPhase 2
Trilaciclib plus chemo for new DLBCL patients
This study tests whether adding a drug called trilaciclib to standard chemotherapy can help people with newly diagnosed Diffuse Large B-Cell Lymphoma. It aims to see if this combination keeps blood counts healthier and improves treatment outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT06532591RecruitingPhase 2
Cadonilimab plus chemo before and after lung cancer surgery
This trial tests a new immunotherapy drug (cadonilimab) combined with standard chemotherapy, given before and after surgery for lung cancer that has very low PD-L1. The goal is to see if this combination helps shrink the tumor and prevents it from coming back.
Chengdu, SichuanAges 18–70 - NCT06586892Recruiting
MRI study to predict jaw injury after radiation therapy
This study uses special MRI scans before and after radiation therapy to see if they can predict damage to your jawbone. If you are getting radiation to the head or neck area, this study may help monitor side effects.
Houston, TexasAges 18 years+ - NCT05844813Enrolling by invitationPhase 4
Neoadjuvant chemo plus targeted treatment for high-risk retroperitoneal sarcoma
This trial tests giving chemotherapy together with a targeted treatment before surgery for people with a high-risk retroperitoneal sarcoma. The goal is to shrink or control the tumor so surgery can potentially remove it with minimal remaining disease (R0/R1).
Beijing, Beijing MunicipalityAges 18–75 - NCT06455046RecruitingPhase 2
New drug combo for advanced cervical cancer
This trial tests a new drug called AK104 combined with chemotherapy and a virus-based therapy for cervical cancer that has come back or spread. It might help people who have already tried standard treatments and need new options.
Fuzhou, FujianAges 18–75 - NCT06770439RecruitingPhase 2
New drug plus chemotherapy for advanced pancreatic cancer
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hangzhou, ZhejiangAges 18 years+ - NCT06596473RecruitingPhase 1
Study of BG-C477 for advanced solid tumors
This trial tests a new drug called BG-C477 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
Goodyear, ArizonaAges 18 years+ - NCT06389552Recruiting
Long-term study of FOLFIRINOX after pancreatic cancer surgery
This study follows people with pancreatic cancer who are receiving a chemotherapy combination called FOLFIRINOX after surgery. The goal is to see how well the treatment works over time and how it affects long-term survival and cancer recurrence.
SeoulAges 19 years+ - NCT06052839RecruitingPhase 2
Pulsed chemo plus pembrolizumab for head and neck cancer
This trial tests a new way to give chemotherapy (pulsed doses) together with pembrolizumab (an immunotherapy) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination works better than standard approaches.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06966440Recruiting
MRD-Guided Chemotherapy After Pancreatic Cancer Surgery
This trial tests whether using a special blood test (MRD) to guide chemotherapy after pancreatic cancer surgery can improve outcomes. It is for people who have had their cancer completely removed and are ready for standard follow-up therapy.
ShanghaiAges 18–75 - NCT07235202RecruitingPhase 1/Phase 2
MR001 plus chemo for advanced pancreatic cancer after first treatment
This trial tests a new drug, MR001, combined with chemotherapy for people whose pancreatic cancer has spread and no longer responds to their first treatment. It aims to see if this combination can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Chemotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chemotherapy?
- Yes. Clin2 currently lists 2,011 recruiting chemotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chemotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chemotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.